Widuranga Kumbukgolla

Dr. Widuranga Kumbukgolla


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2017 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
Panditharathne Nishantha Kumara Wijesekara PanditharathnePanditharathne Nishantha Kumara Wijesekara Panditharathne
Panditharathne Nishantha Kumara Wijesekara Panditharathne
WKWiduranga Kumbukgolla
Widuranga Kumbukgolla
JJJ.A.A.S. Jayaweera
J.A.A.S. Jayaweera
DRDiwan Rawat
Diwan Rawat
Vancomycin is one of the “last-line” classes of antibiotics used in the treatment of life-threatening infections caused by Gram-positive bacteria. Even though vancomycin was discovered in the 1950s, it was widely used after the 1980s for the treatment of infections caused by methicillin-resistant Staphylococci, as the prevalence of these strains were increased. However, it is currently evident that vancomycin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci have developed for various reasons, including the use of avaparcin—an analog of vancomycin—as a feed additive in livestock. Therefore, prophylactic and empiric use of antibiotics and their analogues need to be minimized. Herein we discuss the rational use of vancomycin in treating humans, horses, farm animals, and pet animals such as dogs, cats, and rabbits. In present day context, more attention should be paid to the prevention of the emergence of resistance to antibiotics in order to maintain their efficacy. In order to prevent emergence of resistance, proper guidance for the responsible use of antimicrobials is indispensable. Therefore, almost all stakeholders who use antibiotics should have an in-depth understanding of the antibiotic that they use. As such, it is imperative to be aware of the important aspects of vancomycin. In the present review, efforts have been made to discuss the pharmacokinetics and pharmacodynamics, indications, emergence of resistance, control of resistance, adverse effects, and alternative therapy for vancomycin.

6 May 2019 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
WKWiduranga Kumbukgolla
Widuranga Kumbukgolla
JJJ.A.A.S. Jayaweera
J.A.A.S. Jayaweera
PPPonnamperuma Perera
Ponnamperuma Perera
SHSigi Hale
Sigi Hale

12 November 2016 in Preprints.org
Verified
Preprint
Open access
PDF file
PWP. N. K. Wijesekara
P. N. K. Wijesekara
WKWiduranga Kumbukgolla
Widuranga Kumbukgolla
JJJ.A.A.S. Jayaweera
J.A.A.S. Jayaweera
DRDiwan Rawat
Diwan Rawat
Vancomycin is one of the ‘last-line’ classes of antibiotics used in the treatment of life-threatening infections caused by Gram-positive bacteria. Even though vancomycin was discovered in 1950s it was widely used after 1980s for the treatment of infections caused by methicillin-resistant Staphylococci as prevalence of such strains were increased. However, currently it is evident that vancomycin resistant Staphylococcusaureusandvancomycin-resistant Enterococci have been developed as a result of various reasons including use of avaparcin, which is an analog of vancomycin, as feed additive in livestock. In present day context, more attention should be paid on prevention of emergence of resistance for the antibiotics in order to keep antibiotics effective. In order to prevent emergence of resistance, proper guidance for the responsible use of antimicrobials is indispensable. Therefore, almost all stakeholders who use antibiotics should have in depth understanding on the antibiotic they use. As such, it is imperative to be aware of the important aspects of vancomycin. In the present review, efforts have been made to discussthe pharmacokinetics and pharmacodynamics, indications, emergence of resistance, control of resistance, adverse effects and alternative therapy for vancomycin.